Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma
Source: Targeted Oncology, July 2023
In an interview with Targeted Oncology, Omid Hamid, MD, discussed the efficacy of fianlimab in combination with cemiplimab for advanced melanoma. The results of the study show new possibilities for treating patients who have failed adjuvant anti PD-1 therapy.
Cemiplimab (Libtayo) plus fianlimab (formerly REGN 3767) has demonstrated favorable clinical activity in in patients with advanced melanoma in comparison with FDA-approved immune checkpoint inhibitor (ICI) combinations.
The results come from an analysis of 3 separate expansion cohorts that included adult patients with unresectable or metastatic melanoma, excluding those with uveal melanoma. The population of 98 patients were all naïve to treatment with an anti-PD-L1 agent. Patients had a median age of 68.0 years and were predominantly male (60.2%). Patients identifying as White made up the majority of the population (89.9%). In terms of prior treatment, 2.0% of patients received treatment in the metastatic setting, and 23.5% received systemic therapy in the adjuvant or neoadjuvant settings. Of those who received adjuvant/neoadjuvant therapy, 13.3% had either nivolumab (Opdivo) or pembrolizumab (Keytruda).